(firstQuint)Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema.

 A prospective, multicenter, single arm study.

 The study group will be composed of both type 1 or 2 diabetes mellitus patients with centre involving DME.

 Patients with partial or incomplete response to first-line treatment of at least 4 monthly intravitreal injections and no longer than 12 months of treatment.

 Patients will get treatment to the study eye only (fellow eye will receive standat of care treatment)/ The study eye will receive intravitreal injection of aflibercept 2mg/0.

05ml at enrolment (day 0).

 The next follow up visit will be 4 weeks later.

 At any visit, if sub- or intra-retinal (or both) fluid is present the patient will receive intravitreal injection of aflibercept 2mg/0.

05ml and treatment interval will remain 4 weeks.

 In case that there will not be resolution or improvement (define as decrease in central macular sub-field thickness of 10% or more from the previous visit or gain of one ETDRS line or more), the intravitreal injection of aflibercept will be discontinued after 6 monthly injections and the patient will be followed every 4 weeks.

 If there will be worsening of 10% or more in macular thickness and/or loss of one EDTRS line or more of acuity following treatment discontinuation then injections will be resumed.

 In cases when there will be no sub- or intra-retinal fluid on OCT, a treat and extend regimen (TER) will be applied.

 Patients will receive injection of aflibercept 2mg/0.

05ml, and the follow up interval will be extended by2 weeks.

 Maximal treatment interval will be 4 months.

 At any point where sub- or intra-retinal (or both) fluid will appear after the TER regimen was initiated, the interval between visits and treatments will be reduced back to previous interval which obtained a fluid free macula.

The follow up period will be 52 weeks.

.

 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema@highlight

A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.

05 ml as a Second Line Treatment for Diabetic Macular Edema - TADI Study